Open App →
Back to News Feed
PR Newswire October 24, 2026 neutral

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

AI / LLMSemiconductorsData Center
<p>Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology SEOUL, South Korea, Oct. 24, 2026 /PRNewswire/ -- Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today...</p>
Read original article ↗

Related Articles

Nvidia rejects near-term memory glut fears, leaves CXMT cooperation open

Nvidia CEO Jensen Huang said the company did not expect memory supply to exceed demand in the coming years and remained

Digitimes · October 24, 2026

SpaceX's 80,000-site push turns Starlink from satellite overlay into full mobile challenger

SpaceX has firmly established itself in direct-to-device connectivity through Starlink's expanding satellite constellati

Digitimes · October 24, 2026

AIDC launches Taiwan's largest industrial microgrid with 9MW/54MWh energy storage capacity

Aerospace Industrial Development Corporation (AIDC) held an inauguration ceremony for its 9MW/54MWh large-scale microgri

Digitimes · October 24, 2026

LGES Poland plant nears breakeven as utilization rebounds

LG Energy Solution (LGES)'s Wroclaw plant in Poland, long viewed as a major drag on the business, is nearing profitabili

Digitimes · October 24, 2026